137 -10 (60) 2023 — Abdullayev R.B., Makhmudova L.I. — IMPROVEMENT OF TREATMENT METHODS FOR IRRITABLE BOWEL SYNDROME

IMPROVEMENT OF TREATMENT METHODS FOR IRRITABLE BOWEL SYNDROME

Abdullayev R.B., Urgench branch of the Tashkent Medical Academy Uzbekistan, Khorezm region,  Bukhara State Medical Institute named after Abu Ali ibn Sina

Makhmudova L.I. Urgench branch of the Tashkent Medical Academy Uzbekistan, Khorezm region,  Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The study included 157 patients with IBS who were examined and treated in the Gastroenterology Department of the Bukhara regional Multidisciplinary Medical Center from 2017 to 2022. The average age of patients is 33.2 ± 0.8 years. An anti-histamine, atnf and S – 100 brain-specific protein-containing drug RAAT was found to have a reliable decrease in the amount of inflammatory – calling cytokines-IL-1β, IL-6, ATNF-as well as a reliable increase in the amount of anti-inflammatory cytokines-IL-4, IL-10. This will show the effectiveness of the proposed method. 

Key words: irritable bowel syndrome, cytokines, Colofort

First page

792

Last page

797

For citation: Abdullayev R.B., Makhmudova L.I. – IMPROVEMENT OF TREATMENT METHODS FOR IRRITABLE BOWEL SYNDROME //New Day in Medicine 2023 10(60): 792-797 https://newdaymedicine.com/index.php/2023/12/27/l-696/

LIST OF REFERENCES:

  1. Lacy, B. E. et al. Bowel disorders. // Gastroenterology 2016;150:1393-1407.
  2. Chey W. D., Keefer L., Whelan K. Gibson P. R. Behavioral and diet therapies in integrated care for patients with irritable bowel syndrome. // Gastroenterology 2021;160:47-62.
  3. World Health Organization. Integrated care models: an overview. WHO https://www.researchgate.net/profile/Altynai Satylganova/publication/315493946_Integrated_care_models_an_overview_Copenhagen_WHO_Regional_Office_for_Europe_2016/links/58d2887892851cf4f8f6017e/Integrated-care-models-an-overview Copenhagen-WHO-Regional-Office-for-Europe-2016.pdf (2016).
  4. World Health Organization. Depression and other common mental disorders: global health estimates. WHO https://apps.who.int/iris/bitstream/handle/10665/254610/ WHO-MSD-MER-2017.2-eng.pdf (2017).
  5. Zamani M., Alizadeh-Tabari S. Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. // Aliment. Pharmacol. Ther. 2019;50:132-143.
  6. Liu et al. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. // J. Psychiatr. Res. 2020;126:134-140.
  7. Black C.J. Ford A.C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473-486.
  8. Meringer H., Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. // Nat. Rev.Gastroenterol. Hepatol. 2022;19:345-346.
  9. Drossman D.A. Hasler W.L. Rome IV – Functional GI disorders: disorders of gut–brain interaction. // Gastroenterology 2016;150:1257-1261.
  10. Oka P. et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. // Lancet Gastroenterol. Hepatol. 2020;5:908-917.
  11. Sperber A.D. et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. // Gastroenterology. 2021;160:99-114.

file

download